The investigators propose to conduct a multicenter randomized trial to test whether cilostazol reduces the incidence of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) and improves patients' neurological prognosis, while assessing its safety.
Aged 18-80 years.
Diagnosed with subarachnoid hemorrhage (SAH) by computed tomography (CT) scan, and the responsible aneurysm is clearly identified by computed tomography angiography (CTA) or digital subtraction angiography (DSA).
Received aneurysm coil embolization or craniotomy clipping within 72 hours of symptom onset.
Hunt-Hess grade II-IV.
Multiple aneurysms (>1aneurysms confirmed by CTA/DSA)
Modified Rankin Scale (mRS) score ≥ 3 before onset
Allergy to cilostazol
Severe heart failure（New York Heart Association (NYHA) Functional Classification Grade III or IV）